U.S. FDA Approves Jardiance For The Treatment Of Adults With Chronic Kidney Disease
Portfolio Pulse from Benzinga Newsdesk
The U.S. FDA has approved Jardiance, a drug developed by Eli Lilly and Company (LLY), for the treatment of adults with Chronic Kidney Disease (CKD). The approval is based on the EMPA-KIDNEY phase III trial, which showed that Jardiance significantly reduced the risk of kidney disease progression and cardiovascular death in adults with CKD.
September 22, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The FDA approval of Jardiance for the treatment of CKD could potentially boost Eli Lilly's revenues as it opens up a new market of over 35 million adults in the U.S. suffering from CKD.
The FDA approval of a new drug typically leads to increased sales for the company that developed it. In this case, Eli Lilly's Jardiance has been approved for the treatment of CKD, a condition that affects over 35 million adults in the U.S. This opens up a significant new market for the drug, which could lead to increased revenues for Eli Lilly.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100